Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
7.0
Journals
Antioxidants
Special Issues
Pulmo-Modulatory Factors Affecting the Molecular Pathogenesis of Refractory Lung Diseases
share announcement

Pulmo-Modulatory Factors Affecting the Molecular Pathogenesis of Refractory Lung Diseases

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 4412

Special Issue Editor

Prof. Tsuyoshi Shuto

E-Mail Website
Guest Editor
Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
Interests: chronic obstructive lung diseases; chronic kidney diseases; physical medicine; healthy lifespan; amyloidosis

Special Issue Information

Dear Colleagues,

Defects in the structure and function of respiratory system lead to the development of refractory lung diseases such as chronic obstructive pulmonary diseases (COPDs), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH), for which therapeutic approaches are limited to symptomatic treatments. Generally, its mortality and morbidity are associated with the accumulation of oxidative stress, a condition of imbalance between reactive oxygen species (ROS) formation and cellular antioxidant capacity due to enhanced ROS generation and/or dysfunction of the antioxidant system, so that decreasing oxidative stress directly or indirectly, by certain pulmo-modulatory factors, is crucial for maintaining lung homeostasis. Recent advances in molecular biology, cell biology and developmental biology have led to a generation of various differentiated cells in branching airways and sponge-like alveoli, supporting efficient gas change, while molecular biology, cell biology and human epidemiological study revealed mechanisms of tissue damage responses and diseases, which enables us to understand unique therapeutic targets. This Special Issue aims to collect papers dealing with all aspects of novel pulmo-modulatory factors that are associated with oxidative imbalance in order to provide an updated overview of the state of the art in lung pathophysiology; papers utilizing advanced technologies (molecular pharmacology and genetics, iPS cells, single cell analysis, organoid cultures, etc.) will also be welcome.

Prof. Tsuyoshi Shuto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic obstructive pulmonary diseases (COPD)
  • idiopathic pulmonary fibrosis (IPF)
  • pulmonary hypertension (PH)
  • oxidant/anti-oxidant imbalance
  • animal and cellular models
  • nutraceuticals
  • pharmacology and genetics
  • iPS cells
  • single cell analysis
  • organoid cultures

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2267 KiB  
Article
Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis
by Kosuke Kato, Ioannis Papageorgiou, Yoon-Joo Shin, Jennifer M. Kleinhenz, Sunny Palumbo, Seongmin Hahn, Joseph D. Irish, Skye P. Rounseville, Kenneth S. Knox and Louise Hecker
Antioxidants 2022, 11(3), 492; https://0-doi-org.brum.beds.ac.uk/10.3390/antiox11030492 - 28 Feb 2022
Cited by 7 | Viewed by 3810
Abstract
Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated antioxidant responses. Tecfidera is an orally [...] Read more.
Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated antioxidant responses. Tecfidera is an orally administered FDA-approved drug for the treatment of multiple sclerosis, where the active pharmaceutical ingredient is dimethyl fumarate (DMF), an active Nrf2 activator. However, no studies have evaluated the efficacy of DMF for age-associated persistent lung fibrosis. Here, we demonstrate that in IPF lung fibroblasts, DMF treatment inhibited both TGF-β-mediated pro-fibrotic phenotypes and led to a reversal of established pro-fibrotic phenotypes. We also evaluated the pre-clinical efficacy of lung-targeted (inhaled) vs. systemic (oral) delivery of DMF in an aging murine model of bleomycin-induced persistent lung fibrosis. DMF or vehicle was administered daily to aged mice by oral gavage or intranasal delivery from 3–6 weeks post-injury when mice exhibited non-resolving lung fibrosis. In contrast to systemic (oral) delivery, only lung-targeted (inhaled) delivery of DMF restored lung Nrf2 expression levels, reduced lung oxidative stress, and promoted the resolution of age-dependent established fibrosis. This is the first study to demonstrate the efficacy of lung-targeted DMF delivery to promote the resolution of age-dependent established lung fibrosis. Full article
(This article belongs to the Special Issue Pulmo-Modulatory Factors Affecting the Molecular Pathogenesis of Refractory Lung Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop